Are CSL Limited shares cheap today?

CSL Limited (ASX:CSL) shares continue to fall.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in healthcare giant CSL Limited (ASX: CSL) continued to fall on Wednesday, bringing the total slump in share price to almost 13% since it reported full-year results on August 17. This is in stark contrast to peers Cochlear Limited (ASX: COH) and Sirtex Medical Limited (ASX: SRX) which both surged over 10% after reporting (albeit the latter has given up some of its gains in recent weeks).

Accordingly, with CSL's share price trading at a touch over $100, I thought it was time to revisit this S&P/ASX 20 Index (ASX: XTL) stalwart to see if its current price makes it a buy today.

CSL's results

On the face of it, CSL's results appeared robust. Management reported underlying revenue for the full year was up 8% in constant currency with underlying net profit after tax (NPAT) growing 5% (in constant currency) to $1.24 billion. (Not a bad result for a company with a market capitalisation of $47 billion odd, I must say!).

Nevertheless, the market was seemingly disappointed given CSL's statutory NPAT was down 11% on prior year (in constant currency). The sour grape in CSL's results was the performance of its newly acquired influenza vaccines business – Seqirus. Seqirus was acquired from Novartis AG on 31 July 2015 and disappointed with the business unit reporting sales of only US$652 million due to a weaker influenza season.

Although Seqirus' poor performance contributed a loss to the broader business, dragging group NPAT lower, I believe CSL's share price demise stems from overzealous market expectations, rather than poor results per se. This is arguably because of its high price-earnings multiple of 29x (after the 13% crash to share price).

Outlook

With the market setting such high expectations for CSL, any missed expectations are punished. Despite this, CSL's investment thesis remains intact in my books.

In its full year results, management reassured investors that group NPAT is expected to grow 11% in constant currency for the 2017 year, with earnings per share outstripping profit growth.

If earnings (EBITDA) grow by 14% next year (as guided by the CEO), CSL currently trades on a forward price-earnings of about 25x by my calculations. This makes it cheap by historical standards and worth a second look in my opinion.

Foolish takeaway

CSL is a global leader in blood plasma, immunoglobulin and vaccine products making it immune (pun intended) to economic cycles. Global demand for CSL's life-saving products makes it a solid defensive stock with unrivaled growth potential.

Although it continues to demand high price-earnings multiples, I believe the recent pullback in share price alongside its growth outlook justifies a purchase at present time.

Therefore, given the price slump, I reverse my earlier recommendation and rate CSL a buy today.

Motley Fool contributor Rachit Dudhwala has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »